Interestingly, the NONO/ARAF/CRAF-mediated pERK1/2 activation leads to an increased expression of p300, which leads to increased acetylation and stability of NONO, thus sustaining a positive regulatory feedback loop in drug-resistant melanoma cells. This evidence concerns the gene EP300 and melanoma.